|
FOR IMMEDIATE RELEASE MouthKote® is back!Parnell to reassume sales, marketing & distribution of MouthKote® Oral MoisturizerFebruary 16, 1998 -- Parnell Pharmaceuticals has announced that effective March 1, 1998, it will reassume the sales, marketing & distribution of its MouthKote® oral moisturizer. MouthKote was previously marketed for the last three years under a distribution agreement by Scandipharm, Inc. of Birmingham, Alabama. MouthKote® was developed for the treatment of xerostomia (dry mouth) caused by disease such as cancer or medical therapy. The most severe cases of xerostomia are caused from radiation therapy and surgery to the head and neck. Other causes of xerostomia result from autoimmune diseases such as Sjögren's Syndrome, HIV/AIDS, lupus, and the aging process. However, the leading cause of xerostomia results from the effects of drug therapy, including the use of some analgesics, antihypertensives, decongestants, antihistamines and chemotherapy. In a double-blind, clinical study at the University of Minnesota Dental Clinic, MouthKote was preferred by over 80% of the patients, and it gave the patients relief from dry mouth for more than three times longer than the other products compared. MouthKote® is available through retail pharmacies in eight-ounce and two-ounce bottles. For More Information Contact: |
Send mail to webmaster@parnellpharm.com with questions or comments about
this web site.
|